Search Results

Vaxart, Inc. (NASDAQ: VXRT) has entered into an agreement with Kindred Bioscience, Inc. (“KindredBio”) for the purchase of KindredBio’s manufacturing equipment and sublease of its GMP (Good Manufacturing Practices) manufacturing facility in Burlingame, California, giving Vaxart control of its second GMP manufacturing facility.

Elanco Animal Health Incorporated and Kindred Biosciences, Inc. announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets.

Centaur Biopharmaceutical Services Inc. (Centaur), a wholly-owned subsidiary of Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), today announced an expanded agreement between KindredBio and Vaxart, Inc. (Nasdaq: VXRT) under which Centaur will manufacture Vaxart’s oral vaccine for COVID-19 and other vaccine candidates

The EMA has accepted the submission for review, with the official acceptance date of December 21, 2017.

KindredBio Selected as Second Contract Manufacturing Organization GMP Production for Phase 1 Study Initiated

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field effectiveness study of KIND-014 for the treatment of gastric ulcers in horses.

The primary endpoint was improvement or resolution of fever 6 hours after treatment.

KindredBio will participate in the Bank of America Merrill Lynch Animal Health Summit on February 26, 2018 in New York City.

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced that it has closed its public offering of 4,847,250 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 632,250 additional shares of KindredBio’s common stock, at $9.50 per share, less underwriting discounts and commissions.